Medpace Breast Cancer Awareness Month Highlights
Breast cancer persists as a critical global health challenege, with an estimated 1 in 8 women facing a diagnosis over their lifetime. Advances in early detection and treatment, however, have dramatically improved survival rates; the National Breast Cancer Foundation reports a five-year survival rate nearing 99% when breast cancer is identified in its early stages.
In honor of Breast Cancer Awareness Month, Medpace’s global teams came together to advocate for increased awareness, early screening, and preventative measures against breast cancer, a disease that impacts 2.3 million women annually worldwide. Medpace remains deeply committed to accelerating progress in oncology, leveraging extensive therapeutic expertise to support our Sponsors in the development of tranformaitive cancer therapies.
Medpace’s Global “Think Pink Day”
Throughout October, Medpace assoicates worldwide participated in “Think Pink Day,” expressing solidarity with patients, survivors, and families affected by breast cancer. This inititiative extended across our global footprint, from North America to Asia Pacific, uniting our teams in recognition of breast cancer’s profound impact and the vital importance of advancing research.
Unlock Exclusive Insights: 2024 Clinical Innovations & Considerations for Biopharma
As part of our commitment to elevating clinical research in breast cancer, Medapace presented an exclusive webinar led by Dr. Guarnaschelli, a Senior Medical Director and board-certified radiation oncologist at Medpace.
The session provided an in-depth examination of recent advancements in breast cancer threapeutics, including recent FDA approvals and case studies from industry-leading trials. Dr. Guarnashcelli’s insights spanned key developments in immuno-oncology and precision medicine, offering critical analysis of the latest methodologies reshaping breast cancer treatment paradigms. Watch the webinar today:
Your Cancer Breakthrough Starts Here
At Medpace, we have conducted hundreds of solid tumor studies and are proud to have contributed to many of the latest cancer therapies applied to breast cancer patients utilized today. Our success as a leading oncology CRO is rooted in our unwavering commitment to applying our expertise in oncology, radiation oncology, and imaging, customized to meet the unique demands of each cancer project.